Saturday, July 11, 2026

Drug profile · INN

rubitecan

rubitecan (ORATHECIN) is a dna topoisomerase i inhibitor.

EMA: application withdrawn
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — rubitecan
Class
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

rubitecan (ORATHECIN) is a dna topoisomerase i inhibitor.

Key facts

INN rubitecan
Brand ORATHECIN
Mechanism DNA topoisomerase I inhibitor
Target DNA topoisomerase 1

Mechanism of action

DNA topoisomerase I inhibitor

Primary target: DNA topoisomerase 1

Approval history

Authority Status Date
EMA application withdrawn

Related & competitor drugs

  1. etirinotecan pegol Antineoplastic and immunomodulating agents (L01)
  2. irinotecan hydrochloride DNA topoisomerase I inhibitor
  3. fam-trastuzumab deruxtecan-nxki DNA topoisomerase I inhibitor
  4. sacituzumab govitecan-hziy DNA topoisomerase I inhibitor
  5. topotecan hydrochloride DNA topoisomerase I, mitochondrial inhibitor
  6. datopotamab deruxtecan Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is rubitecan?

rubitecan (ORATHECIN) is a dna topoisomerase i inhibitor.

What is the brand name for rubitecan?

ORATHECIN is a marketed brand name for rubitecan. Check FDA Drugs@FDA for the current US label holder and prescribing information.